See analyst estimates and all valuation multiples for Chemicals
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $227B | 6.8x | 17.4x | |
| $96.4B | 4.1x | 21.2x | |
| $73.8B | 4.7x | 20.2x | |
| $73.0B | 6.0x | 14.2x | |
| $61.6B | 0.9x | 7.3x | |
| $48.5B | 1.3x | 9.2x | |
| $40.7B | 3.0x | 15.6x | |
| $39.9B | 2.3x | 6.0x | |
| $37.3B | 1.4x | 7.8x | |
| $36.5B | 17.4x | 435.7x | |
| $36.1B | 1.4x | 6.7x | |
| $35.5B | 0.8x | 6.6x | |
| $33.3B | 1.1x | 9.4x | |
| $30.0B | 2.4x | 9.4x | |
| $28.3B | 6.7x | 18.2x | |
| $27.9B | 0.7x | 6.6x | |
| $27.9B | 1.8x | 9.7x | |
| $27.8B | 2.5x | 12.8x | |
| $27.4B | 2.0x | 11.6x | |
| $26.5B | 6.6x | 36.7x | |
| $24.4B | 4.1x | 10.2x | |
| $24.4B | 0.7x | 5.9x | |
| $19.5B | 3.7x | 11.1x | |
| $18.3B | 1.6x | 10.5x | |
| $17.9B | 4.1x | 16.5x | |
| $17.8B | 2.0x | 8.9x | |
| $17.1B | 0.5x | 2.2x | |
| $16.6B | 3.0x | 14.6x | |
| $16.3B | 1.6x | 7.2x | |
| $15.6B | 2.1x | 13.6x | |
| $14.6B | 0.9x | 12.3x | |
| $14.5B | 3.0x | 10.9x | |
| $14.3B | 6.1x | 21.1x | |
| $13.9B | 1.1x | 6.2x | |
| $13.6B | 2.3x | 6.0x | |
| $13.3B | 1.1x | 8.2x | |
| $13.2B | 1.4x | 7.3x | |
| $13.0B | 2.8x | 8.5x | |
| $12.3B | 0.8x | 5.5x | |
| $11.3B | 2.1x | 10.3x | |
| $11.3B | 0.8x | 5.2x | |
| $11.3B | 0.6x | 7.1x | |
| $10.1B | 3.4x | 9.3x | |
| $10.0B | 4.6x | 10.8x | |
| $9.1B | 1.4x | 5.4x | |
| $8.7B | 1.7x | 13.7x | |
| $7.8B | 1.8x | 8.6x | |
| $7.7B | 1.1x | 5.1x | |
| $7.6B | 0.7x | 4.6x | |
| $7.0B | 0.5x | 2.5x | |
| $6.6B | 3.1x | 9.4x | |
| $6.2B | 2.7x | 583.8x | |
| $5.9B | 6.3x | 22.9x | |
| $5.5B | 1.2x | 9.9x | |
| $5.0B | 1.3x | 8.6x | |
| $4.8B | 0.9x | 4.3x | |
| $4.7B | 1.8x | 13.8x | |
| $4.7B | 0.7x | 7.0x | |
| $4.6B | 1.0x | 6.0x | |
| $4.4B | 0.5x | 4.7x | |
| $4.2B | 0.4x | 15.4x | |
| $4.1B | 0.7x | 5.0x | |
| $3.9B | n/a | n/a | |
| $3.9B | 5.4x | 18.5x | |
| $3.7B | 1.7x | 8.1x | |
| $3.5B | 12.6x | 40.6x | |
| $3.2B | 0.8x | 14.8x | |
| $3.1B | 5.0x | 27.8x | |
| $2.6B | 6.2x | 20.1x | |
| $2.6B | 0.7x | -314.1x | |
| $2.5B | 0.6x | 4.2x | |
| $2.2B | 0.2x | 7.3x | |
| $2.2B | n/a | n/a | |
| $1.9B | 2.1x | 11.3x | |
| $1.8B | 0.7x | 5.6x | |
| $1.6B | 6.9x | n/a | |
| $1.5B | 1.3x | 9.7x | |
| $1.2B | 2.4x | n/a | |
| $1.2B | n/a | n/a | |
| $1.2B | 0.3x | 5.2x | |
| $1.2B | 1.2x | 11.4x | |
| $1.1B | 1.9x | 9.7x | |
| $1.1B | 1.5x | 6.4x | |
| $965M | n/a | n/a | |
| $877M | 0.6x | 5.4x | |
| $690M | 0.4x | 9.8x | |
| $574M | 1.1x | 7.9x | |
| $539M | 0.5x | n/a | |
| $539M | 0.5x | 4.2x | |
| $518M | 1.3x | 8.7x | |
| $396M | 0.3x | 4.3x | |
| $327M | 1.3x | 9.5x | |
| $307M | 0.6x | 2.1x | |
| $297M | 0.5x | 6.7x | |
| $289M | 0.2x | 2.9x | |
| $288M | 0.6x | 4.2x | |
| $189M | n/a | n/a | |
| $154M | 2.9x | -3.2x | |
| $151M | 4.3x | -4.6x | |
| $145M | 0.3x | 4.1x | |
| $130M | 11.4x | -4.5x | |
| $126M | 0.6x | 3.4x | |
| $115M | 1.1x | 5.8x | |
| $82.9M | n/a | n/a | |
| $67.7M | n/a | n/a | |
| $65.2M | n/a | n/a | |
| $58.9M | 1924.0x | -10.6x | |
| $44.7M | 1.4x | -2.7x | |
| $40.4M | n/a | n/a | |
| $39.8M | 0.6x | 33.8x | |
| $21.1M | n/a | n/a | |
| $21.1M | 51.0x | -1.8x | |
| $19.0M | 1.8x | -12.9x | |
| $12.2M | 3.4x | -1.9x | |
| $5.1M | n/a | n/a | |
| $0.2M | n/a | n/a | |
| -$3.5M | -2.2x | 0.1x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Chemicals